Upregulation of TCF1 and BCL11B in CD8+ effector T cells predicts favorable response to ibrutinib in patients with chronic lymphocytic leukemia
Ge Liu, Taotao Liang, Hao Ai, Shan Wang, Songke Yin, Xiaojiao Wang, Hongfei Wu, Qian Wang, Hongmian Zhao, Xiaojuan Liu, Xiaodong Luv, Jia Liu, Qingsong Yin · 2026
Read Upregulation of TCF1 and BCL11B in CD8+ effector T cells predicts favorable response to ibrutinib in patients with chronic lymphocytic leukemia by Ge Liu, Taotao Liang, Hao Ai, Shan Wang, Songke Yin, Xiaojiao Wang, Hongfei Wu, Qian Wang, Hongmian Zhao, Xiaojuan Liu, Xiaodong Luv, Jia Liu, Qingsong Yin (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13369674.txt.
Description
Ge Liu and co-authors present a 2026 study on a drug for a slow blood cancer. The drug, ibrutinib, is a mainstay for chronic lymphocytic leukemia. Past work linked two gene switches in T cells to better survival. The team asked if those switches track response to the drug. They mined four public data sets and checked a group of 98 patients.
Treatment raised the share of killer T cells and lifted both switches. A new subset of killer cells, marked by both switches, was near absent before treatment. It grew after treatment in patients who did well. In poor responders, the switch link did not form. The subset may signal a rebuilt immune response.
Catalog record
| CREATOR | Ge Liu, Taotao Liang, Hao Ai, Shan Wang, Songke Yin, Xiaojiao Wang, Hongfei Wu, Qian Wang, Hongmian Zhao, Xiaojuan Liu, Xiaodong Luv, Jia Liu, Qingsong Yin |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 41 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |